All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Reported results | 2005-000295-41 | Double-blind,placebo-controlled cross-over study for evaluation of the efficacy of the PDE-5-inhibitor vardenafil on the peripheral perfusion and the clinical symptomatology of patients with Raynaud´s... | 2010-04-07 | due-trials |
Reported results | 2005-001596-34 | Multicentre phase II trial of Bendamustine in combination with rituximab for patients with previously untreated or relapsed chronic lymphocytic leukemia | 2012-07-11 | due-trials |
Ongoing | 2005-003156-35 | Efficacy and tolerability of Ziprasidone vs. Clozapine in the treatment of dually diagnosed (DD-) patients with schizophrenia and cannabis use disorder: A randomised study | not-yet-due | |
Reported results | 2005-003271-21 | Doppelblinde, prospektive, randomisierte, monozentrische, placebo-kontrollierte Pilotstudie zur Wirksamkeit und Sicherheit von Moxifloxacin in der Prophylaxe der Bakteriämie nach Hochdosis-Chemotherap... | 2008-12-17 | due-trials |
Reported results | 2005-003516-29 | Prospective, randomized, double-blinded clinical trial on remifentanil for analgesia and sedation of ventilated neonates and infants | 2010-04-11 | due-trials |
Exempt, with results Terminated | 2005-004139-23 | An open-label, non-randomized phase I/II trial of neoadjuvant radio-immunochemotherapy with cetuximab and 5-FU for advanced rectal cancer | not-yet-due | |
Reported results | 2005-005393-73 | A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT- PET for Early Prediction of Non-Progression in Patients with Advanced Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and to A... | 2010-10-18 | due-trials |
Reported results Terminated | 2005-005612-24 | PHASE II STUDY OF CETUXIMAB FOR THE TREATMENT OF REFRACTORY OR RELAPSED MULTIPLE MYELOMA EMMA-1 (ERBITUX FOR MULTIPLE MYELOMA) | 2010-06-26 | due-trials |
Reported results | 2006-001936-30 | A phase II dose escalation study of caspofungin in patients with invasive aspergillosis | 2009-10-26 | due-trials |
Reported results Terminated | 2007-000224-41 | A double-blind, multicentre, parallel group, randomised, controlled trial to evaluate the possible benefit of isoniazid dose adjustment according to the genotype for NAT2 (arylamine N-acetyltransferas... | 2010-09-15 | due-trials |
Exempt, with results | 2007-000233-18 | Phase I/II Studie zum Einsatz von Capecitabin und Oxaliplatin (XELOX) in Kombination mit Bevacizumab und Imatinib in der Erstlinientherapie von Patienten mit fortgeschrittenem kolorektalem Karzinom | 2012-06-19 | not-yet-due |
Reported results | 2007-001573-28 | Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial. | 2014-10-28 | due-trials |
Reported results | 2007-002824-13 | Prospective, placebo-controlled blinded clinical trial to study the efficacy of orally administered Glucose 20% for relieving pain during nasopharyngeal suctioning in preterm infants > 1500g under CP... | 2010-07-17 | due-trials |
Reported results | 2007-003187-22 | Clinical trials for adults HD18 for advanced stages Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; treatment stratification by means of FDG-PET Therapi... | 2019-07-18 | due-trials |
Reported results | 2007-003467-48 | A randomized phase II study of prednisone, vinblastine, doxorubicin, and gemcitabine in patients with intermediate stage Hodgkin's lymphoma | 2013-11-17 | due-trials |
Reported results | 2007-004474-24 | HD 16 for early stages: treatment optimization trial in the first-line treatment of early stage Hodgkin lymphoma; treatment stratification by means of FDG-PET. | 2020-12-29 | due-trials |
Reported results | 2007-005920-34 | HD17 for Intermediate Stage Hodgkin Lymphoma - Treatment Optimization Trial in the First-Line Treatment of intermediate Stage Hodgkin lymhoma; Therapy stratification by means of FDG-PET | 2020-03-21 | due-trials |
Reported results | 2007-007587-21 | Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic l... | 2018-01-01 | due-trials |
Reported results | 2008-000896-30 | Surfactant application during spontaneous breathing with CPAP or during mechanical ventilation in the therapy of IRDS in premature infants <27 weeks | 2012-06-21 | due-trials |
Reported results | 2008-001421-34 | Phase II Trial of Combined Immunochemotherapy with Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients with Previously Treated or Untreated T-Prolymphocytic Leuke... | 2014-05-29 | due-trials |
Reported results | 2008-008896-32 | Memory, Ageing, and the Cholinergic System a combined fMRI and PET study | 2014-05-07 | due-trials |
Reported results Terminated | 2009-010700-28 | GRANITE-1 - Granulocyte-transfusions for patients with febrile neutropenia Granulozytentransfusionen bei Patienten mit febriler Neutropenie (GRANITE) | 2015-12-02 | due-trials |
Reported results | 2009-012607-26 | MIMEB - Molecular Imaging with erlotinib and bevacizumab. A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET and DCE-MRI for Early Prediction of Non-Progression in Patients with Advanc... | 2013-12-13 | due-trials |
Exempt | 2009-012957-39 | A phase I/II safety and efficacy trial of a combination of bendamustine, rituximab and lenalidomide (BRL) in patients with relapsed or refractory chronic lymphocytic leukemia | 2015-02-12 | not-yet-due |
Reported results | 2009-015217-52 | Pilotstudie zur Pyridoxalphosphattherapie bei Patienten mit primärer Hyperoxalurie Typ I - Pilot trial on treatment of patients with primary hyperoxaluria type I with pyridoxal-phosphate | 2012-09-19 | due-trials |
Exempt, with results | 2010-021086-73 | HD-R3i - A prospective, randomized, placebo-controlled, international, multicenter phase I/II trial of RAD001 (everolimus) in combination with DHAP as induction therapy in patients with relapsed or re... | 2018-12-31 | not-yet-due |
Reported results | 2010-022058-18 | A PHASE II STUDY TO INVESTIGATE THE EFFICACY OF CYCLOPHOSPHAMIDE AS SOLE GRAFT-VERSUS-HOST-PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (OCTET-CY) | 2013-11-18 | due-trials |
Reported results | 2010-022180-35 | Ofatumumab in relapsed nodular lymphocyte predominant Hodgkin Lymphoma | 2015-04-22 | due-trials |
Reported results | 2011-000911-26 | Heart rate control after acute myocardial infarct | 2014-02-24 | due-trials |
Not reported | 2011-001795-19 | STATIN RECAPTURE THERAPY BEFORE CORONARY ARTERY BYPASS GRAFTING (ACRONYM: START-CABG TRIAL) | 2020-04-27 | due-trials |
Reported results | 2011-003473-29 | Trial on treatment with inhaled furosemide of preterm and term neonates with transient tachypnoea Inhalatives Furosemid bei Frühgeborenen und Neugeborenen mit Transitorischer Tachypnoe | 2015-07-09 | due-trials |
Completed, but no date, and reported results | 2011-004593-29 | Phase II trial of metronomic treatment in children and adolescents with recurrent or progressive neuroblastoma | bad-data | |
Reported results | 2011-004698-98 | A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of lenalidomide (Revlimid®) as maintenance therapy for high-risk pateints with chr... | 2021-01-14 | due-trials |
Reported results | 2011-005082-21 | Targeted BEACOPP variants in patients with newly diagnosed advanced classical Hodgkin Lymphoma Targeted BEACOPP Varianten für Patienten mit Erstdiagnose eines fortgeschrittenen klassischen Hodgkin ... | 2016-10-15 | due-trials |
Reported results | 2011-005628-16 | FTO-genotype dependent weight reduction under treatment with bromocriptin in obese patients Gewichtsreduktion bei Adipositas unter der Therapie mit Bromocriptin in Abhängigkeit vom FTO-Genotyp | 2015-06-03 | due-trials |
Reported results | 2011-005655-13 | A phase II trial to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 - overexpression or - amplification or - mutation. | 2016-06-09 | due-trials |
Reported results | 2011-005797-32 | Effentora® for Dyspnoea (EffenDys) - Fentanyl buccal tablet (FBT) for the relief of episodic dyspnoea (ED) in cancer patients: an open label, randomized, morphine-controlled, crossover, phase II trial | 2014-10-29 | due-trials |
Reported results | 2012-002887-29 | Translational therapy in patients with Osteogenesis imperfecta - a pilot trial on treatment with the RANKL-antibody Denosumab | 2015-01-26 | due-trials |
Reported results | 2012-003696-18 | Effect of a preinterventional calorie restriction on renal function after contrast agent exposition in patients at risk. Einfluss einer präinterventionellen kalorienreduzierten Diät auf die Nierenf... | 2016-10-07 | due-trials |
Reported results | 2013-000577-77 | EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION ACRONYM: SABATO (Staphylococcus aureus Bacteremia Antibiotic Treatment Options) | 2020-03-31 | due-trials |
Reported results Terminated | 2013-002036-24 | A non-randomised, non-comparative monocenter investigator initiated trial to assess the efficacy and safety of Carmustine in patients with BRCA1/2-associated advanced breast and ovarian cancer | 2016-09-15 | due-trials |
Reported results | 2013-002737-38 | A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations | 2020-02-29 | due-trials |
Reported results Terminated | 2013-003048-21 | CONTROLING INTESTINAL COLONIZATION OF HIGH-RISK PATIENTS WITH EXTENDED- SPECTRUM BETALACTAMASE PRODUCING ENTEROBACTERIACEAE (ESBL-E) – A RANDOMIZED TRIAL (CLEAR) Kontrolle der intestinalen Kolonisi... | 2017-05-31 | due-trials |
Reported results | 2013-003211-22 | A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib vs. Placebo in Previously Untreated Binet Stage A CLL Patients wi... | 2022-07-11 | due-trials |
Reported results | 2013-003369-33 | JeRiCHO (JAK-inhibition in recurrent classical Hodgkin Lymphoma): A phase II, open-label, prospective, non-randomized, multicenter clinical trial with the JAK-inhibitor ruxolitinib in patients with re... | 2019-06-30 | due-trials |
Reported results | 2013-003990-89 | Brentuximab vedotin or B-CAP in the treatment of older patients with newly diagnosed classical Hodgkin Lymphoma - a GHSG-NLG Intergroup Phase II trial- Brentuksimabivedotiini vai B-CAP hoito iäkkä... | 2022-03-16 | due-trials |
Reported results Terminated | 2013-004481-34 | RANDOMIZED PHASE 2 TRIAL COMPARING EXPERIMENTAL IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 S.C.,GM-CSF) IN RECURRENT HIGH RISK NEUROBLASTOMA PATIENTS WITH STANDARD IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 ... | 2016-10-28 | due-trials |
Reported results | 2014-000569-35 | A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 and ibrutinib (BIG) followed by ibrutinib and GA101 ... | 2019-03-29 | due-trials |
Ongoing | 2014-000580-40 | A prospective, open-label, multicentre phase-II-trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by GA101 (Obinutuzumab) and ABT-199 (Venetoclax) followed by ... | not-yet-due | |
Reported results | 2014-000582-47 | A prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by ... | 2022-03-09 | due-trials |
Reported results | 2014-000590-39 | A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by ofatumumab and ibrutinib followed by ibrutinib and ofatumu... | 2020-02-06 | due-trials |
Reported results | 2014-004036-19 | GHSG-AFM13 An open-label, randomized, multicenter phase II trial with AFM13 in patients with relapsed or refractory Hodgkin Lymphoma GHSG-AFM13 Eine offene, randomisierte, multizentrische Phase II ... | 2020-01-31 | due-trials |
Ongoing | 2014-005130-55 | HD21 for advanced stages: Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparision of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD. | not-yet-due | |
Reported results Terminated | 2015-000568-32 | Obinutuzumab containing conditioning regimen for CLL patients and patients with Richter`s transformation requiring an allogeneic stem cell transplantation | 2019-09-30 | due-trials |
Reported results | 2015-003128-30 | Phase II trial of the Btk-inhibitor Ibrutinib in patients with relapsed nodular lymphocyte-predominant Hodgkin Lymphoma (NLPHL) Phase II-Studie mit dem Btk-Inhibitor Ibrutinib zur Behandlung des re... | 2020-05-20 | due-trials |
Reported results Terminated | 2015-004731-12 | Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients with Retinal Detachment | 2020-06-15 | due-trials |
Completed, report not yet due | 2015-004936-36 | A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus venetoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) versus... | 2024-02-29 | not-yet-due |
Reported results | 2016-002626-37 | Nivolumab and AVD in earlystage unfavorable classical Hodgkin lymphoma - A GHSG randomized, multicenter phase II trial Nivolumab und AVD für Patienten mit klassischem Hodgkin Lymphom im intermediär... | 2022-07-20 | due-trials |
Completed, report not yet due | 2016-003334-25 | A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in relapsed lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition ... | 2023-11-20 | not-yet-due |
Completed, reported early | 2017-003133-28 | A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab), acalabrutinib (ACP-196) and ABT-199 ... | 2023-09-26 | not-yet-due |
Reported results Terminated | 2017-003221-15 | PROSPEKTIV RANDOMISIERTE, MULTIZENTRISCHE STUDIE ZUM VERGLEICH DER EINER RADIKALEN HYSTEREKTOMIE NACH NEOADJUVANTER CHEMOTHERAPIE VERSUS EINER PRIMÄREN RADIOCHEMOTHERAPIE BEI PATIENTINNEN MIT EINEM ZE... | 2022-08-09 | due-trials |
Listed as ongoing, but also has a completion date | 2017-003334-82 | Abscopal Effect of Radiotherapy and Nivolumab in anti-PD1 Pretreated Relapsed or Refractory classical Hodgkin Lymphoma - An international multicenter Phase II trial | 2024-05-04 | bad-data |
Ongoing | 2017-004883-37 | Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients (NB2015-LR) | not-yet-due | |
Reported results Terminated | 2018-000399-13 | A phase II trial to evaluate efficacy and safety of erdafitinib in patients with advanced NSCLC harbouring FGFR genetic alterations after relapse of standard therapy | 2022-10-14 | due-trials |
Ongoing | 2018-000873-59 | Consolidation Therapy with Brentuximab Vedotin after Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma Konsolidierungstherapie mit Brentuximab Vedotin nach allogener ... | not-yet-due | |
Other | 2018-002492-17 | A prospective, open-label, multicentre Phase-II-Trial to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK Inhibitor, plus tislelizumab (BGB-A317), a PD-1 Inhibitor, for treatment of ... | not-yet-due | |
Ongoing | 2018-003048-22 | A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal ad... | not-yet-due | |
Other | 2018-003270-27 | A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine fol-lowed by obinutuzumab (GA101), zanubrutinib (BGB-3111) and ve-neto... | not-yet-due | |
Reported results Terminated | 2019-000914-12 | Gazyvaro Targeting Tumor Promoting, Regulatory B-cells in Solid Tumors Gazyvaro (Obinutuzumab) als zielgerichtete Therapie gegen Tumorwachstum fördernde, regulatorische B-Zellen bei soliden Tumoren | 2022-03-17 | due-trials |
Completed, report not yet due | 2019-002036-90 | A randomized, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of subcutaneous Dupilumab in localized scleroderma Randomisierte, Placebo kontrollierte klinische Phase... | 2023-11-30 | not-yet-due |
Ongoing | 2019-002734-37 | Open-Label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy with Liposomal Irinotecan Combined with Oxaliplatin and 5-Fluorouracil/Folinic ... | not-yet-due | |
Reported results Terminated | 2019-002930-35 | Phase II trial of TisaGenlecleucel in Elderly Patients with First-Relapsed or Primary Refractory Agressive B-cell Non-Hodgkin Lymphoma | 2023-02-24 | due-trials |
Other | 2019-003854-99 | A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients... | not-yet-due | |
Ongoing | 2019-003856-35 | Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-DADA) Daratumumab als Primärtherapie bei nichttransplantat... | not-yet-due | |
Other | 2020-002142-17 | CLL-Frail – A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients CLL-Frail – Eine prospektive, multizentrische Phase II Studie mit Acalabrutinib bei s... | not-yet-due | |
Reported results | 2020-002788-80 | An explorative study to assess the safety, tolerability, and efficacy of AZD4831 in the treatment of pulmonary arterial hypertension (PAH) (MPO-PAH) Explorative Studie zur Bewertung der Sicherheit,... | 2021-12-21 | due-trials |
Exempt, with results | 2020-003503-34 | A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals Eine Phase-1/2a-Studie der intrav... | 2021-08-11 | not-yet-due |
Other | 2020-004360-26 | A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZUMAB AND VENETOCLAX (GVE) IN PREVIOUSLY UNTREATED PATIENTS WI... | not-yet-due | |
Exempt, with results | 2020-004448-27 | A Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals Eine Phase-1/2a-Studie zur inhalative... | 2021-09-23 | not-yet-due |
Exempt, with results Terminated | 2021-000417-16 | A Phase I / randomized Phase II trial to analyse safety and efficacy of human SARS-CoV 2 specific T lymphocyte transfer in patients with COVID-19 in need of treatment or at risk of severe COVID-19 ... | 2022-08-03 | not-yet-due |
Completed, report not yet due | 2021-004526-29 | A MULTINATIONAL, PHASE 2, RANDOMISED, ADAPTIVE PROTOCOL TO EVALUATE IMMUNOGENICITY AND REACTOGENICITY OF DIFFERENT COVID-19 VACCINES ADMINISTRATION IN OLDER ADULTS (≥75) ALREADY VACCINATED AGAINST SAR... | 2023-11-30 | not-yet-due |
Ongoing | 2021-005949-33 | Prospective, single-arm trial of neoadjuvant nivolumab plus ipilimumab in patients with localized renal cell carcinoma who are at a high risk of relapse after radical nephrectomy (NEONIRenCa) | not-yet-due |